Visoluten®
RESEARCH METHODS
All patients before and after the course of treatment were examined according to a comprehensive
clinical program, including, along with the obligatory - traditional methods, methods for diagnosing and
clarifying visual impairment, blood flow velocity, the state of the outer and inner layers of the retina,
the state of the retinal pigment epithelium.
Traditional examination methods included: a study of visual acuity and visual field, a study of dark
adaptation, a study of intracranial pressure, biomicroscopy of the anterior segment of the eyes, deep
optical media, biomicro-ophthalmoscopy, stereophthalmoscopy, direct ophthalmoscopy.
Diagnostic and clarifying examination methods included: visocontrastometry, static and multiple
central perimetry, color perception study, fundus fluorescence angiography, Doppler sonography,
electrophysiological studies.
A general clinical study of blood and urine, a biochemical study of blood on the apparatus «REFLOTRON»
(Boehringer Mannheim, Germany) were carried out.
RESEARCH RESULTS
Evaluation of clinical and laboratory functional parameters revealed changes in all parts of the eyeball
(iris, lens, vitreous body, optic nerve) in patients with degenerative diseases of the retina, which means
generalization of the pathological process with a tendency to progress as the disease progresses.
As a result of the studies, it was found that in the case of application of VISOLUTEN® in addition to
the conventional treatment, the maximum therapeutic effect was observed in patients with the initial
stages of degenerative changes in the retina. This was manifested in an increase in visual acuity and an
improvement in the electrophysiological parameters of the retina, the results of fluorescent angiography,
and changes in visual fields (expansion of the peripheral boundaries, reduction or disappearance of
paracentral scotomas). The research results are presented in tables 2 and 3.
Influence of VISOLUTEN® on the dynamics of visual acuity in patients Table 2
with degenerative diseases of the retina.
Visual acuity index Before treatment, (%) After Treatment with After Treatment with
Conventional Methods, (%) VISOLUTEN®, (%)
0,0 to 0,1 35,7 28,3 16,5
0,2 to 0,8 56,2 61,9 67,8
0,9 to 1,0 8,1 9,8 15,7
So, from the data in Table 2, it can be seen that when additional VISOLUTEN® was included in the
treatment regimen for patients of the primary group, visual acuity significantly increased in most
patients: the number of patients with visual acuity from 0.9 to 1.0 increased from 8.1% to 15, 7%, and
patients with visual acuity from 0.2 to 0.8 - from 56.2 to 67.8%, while the number of patients with
visual acuity below 0.1 - from 35.7% to 16.5 %. The pain indicators in the control group indicate the
insufficient effectiveness of the conventional treatment: the number of patients with visual acuity from
0.9 to 1.0 after the course of treatment remained practically unchanged, and the number of patients
with low visual acuity (from 0.0 to 0.1 ) decreased slightly - from 35.7% to 28.3%.
These data are consistent with the results of the electrophysiological study shown in Table 3. From
the data in Table 3, it can be seen that the electroretinography indices of both the «A» and «B»
waves, with the additional inclusion of VISOLUTEN®in the treatment regimen, significantly increase
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.